Chabiotech Co. Ltd. | Mutual Funds
Mutual Funds that own Chabiotech Co. Ltd.
DFA Emerging Markets Small Cap Series
344,944
0.66%
0
0.08%
01/31/2018
DFA Emerging Markets Core Equity Portfolio
153,524
0.28%
-2,534
0.01%
04/30/2018
Eaton Vance Parametric Tax Managed Emerging Markets Fund
115,772
0.22%
0
0.06%
06/30/2018
48,918
0.09%
0
0.34%
09/06/2018
Government Pension Fund - Global (The)
37,639
0.07%
-316,916
0%
12/31/2017
SPDR S&P International Small Cap ETF
27,673
0.05%
0
0.06%
09/06/2018
Dimensional Funds ICVC - Emerging Markets Core Equity Fund
10,033
0.02%
0
0.01%
12/31/2017
5,530
0.01%
206
0.03%
07/31/2018
DFA TA World (ex-US) Core Equity Portfolio
5,500
0.01%
0
0%
04/30/2018
5,480
0.01%
0
0.02%
09/05/2018
| Address |
3rd Floor, Pie'n Polus Building
Seoul SL 06062
Korea, Republic Of
|
|
Employees
|
- |
| Website |
http://www.chabio.co.kr |
| Updated |
09/14/2018 |
| Cha Biotech Co., Ltd. engages in the research of cell therapy and storage of cord blood. It operates through the following business: Cell Therapy Development, Bio, Chaum, and Bio Insurance. The Cell Therapy Development business develops and commercializes cell therapy. |
